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Abstract 
 
Gefitinib is a medication that was originally developed as an epidermal growth factor 
receptor (EGFR) blocker. It has been used to treat non-small cell lung cancer with 
varying success. We describe a patient who presented with Pancoasts syndrome and was 
deemed surgically unresectable.  He had limited success with chemotherapy and radiation 
but had an excellent response to the medication gefitinib. The patient was disease free for 
several years and after eleven years of follow up with CT scans, a PET CT showed an 
isolated area of FDG avidity which on biopsy was small cell carcinoma of the lung. The 
patient had been maintained continually on gefitinib (Iressa) for eleven years.  Gefitinib 
treatment and continuing EGFR blockade invariably result in resistance to the medication 
and ultimate relapse. However in the present case, presumed sensitivity of the original 
tumor for a prolonged time period was noted, with development of either a new, small 
cell lung cancer, or histologic transformation. Similar cases have described this 
phenomenon of epithelial cancers treated with tyrosine kinase inhibitor blockade and 
development of small cell lung cancer; however, our case is unusual in that this 
transformation is observed over an eleven year time span. 
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Introduction 
 
Lung cancer is a leading cause of mortality worldwide.  Overall survival has lagged 
behind the improved survival seen with breast cancer, prostate cancer and colorectal 
cancer patients.1 A significant number of patients with lung cancer present at an advanced 
stage.  CT screening aims to find patients with disease much earlier in their natural 
history.    
 
The treatment of advanced non-small cell carcinoma of the lung with chemotherapy 
and/or radiation has been the mainstay of therapy.  Newer medications with fewer side 
effects aim to improve survival, while preserving quality of life.  Current therapies have 
focused on different inhibitors of the components of tumor biology.  Monoclonal 
antibodies, such as Bevacizumab, can block angiogenesis by inhibiting vascular 
endothelial growth factor A.  Epidermal growth factor receptor blockers, in the form of 
tyrosine kinase inhibitors, have been developed to block the EGFR ligand.  EGFR can be 
activated by epidermal growth factor and TGF alpha.   EGFR plays an important role in 
cell proliferation, and mutations that activate this pathway promote cell proliferation and 
survival. Examples of agents that block EGFR include erlotinib (Tarceva), gefitinib 
(Iressa), afatinib and oimertinib.2 Erlotinib has been shown to be effective in the 
treatment of tumors with EGFR activity translating into improved survival.3 
Unfortunately, most patients ultimately develop resistance.   
 
The biology of resistance mechanisms of lung cancer to medical therapy is complex and 
is still poorly understood. The consequences of prolonged EGFR blockade are unknown, 
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but in most cases relapse of the original tumor occurs.4 We describe a case of a patient 
with advanced right sided superior sulcus (Pancoast tumor) of the lung who had a poor 
response to chemotherapy and radiation.  The patient responded extremely well to 
gefitinib.  After ten years of CT surveillance the patient developed an isolated area of 
biopsy proven small cell lung cancer in the bronchus intermedius and right middle lobe.  
The new site of FDG uptake was different when compared to the patient’s initial tumor 
presentation site.  He is currently receiving systemic chemotherapy and radiation 
treatment.  Previous studies have reviewed the clinical characteristics of transformed 
small cell lung cancer and whether this represents a new subtype of small cell carcinoma. 
 
Case report 
 
A 55 year old Caucasian male with a prior smoking history presented twelve years ago 
with symptoms attributed to Pancoast syndrome. Symptoms included neuropathy due to 
locally advanced malignancy.  Biopsy revealed an undifferentiated non-small cell lung 
carcinoma without typical squamous although with some glandular differentiation.  
Radiologically, the tumor was locally invasive into the surrounding mediastinal structures 
and the patient was deemed not a surgical candidate. He was initially treated with 
conventional chemotherapy and radiation but had a relatively poor response 
radiologically and clinically. He was then commenced on the medication gefitinib in 
April 2004 and was noted to have a sustained response to therapy.  There was interval 
resolution of tumor mass as assessed by follow up CT scans.  No genetic testing was 
available at that time, and his mutation status was unknown.  The patient had ceased to 
smoke at the time of his original lung cancer diagnosis twelve years ago. 
 
His dramatic radiologic and clinical response perhaps implied that he very likely had an 
EGFR activating mutation.  He was maintained on gefitinib for eleven years in remission, 
and maintained an excellent performance status.  Past medical history included 
myocardial infarction and a left nephrectomy.  He had no occupational exposure. The 
patient had never used oxygen at home and was able to climb a flight of stairs with 
relative ease.  Blood tests were normal.   
 
As part of ongoing surveillance, a chest CT scan prompted a PET/CT scan which showed 
a new area of FDG avidity, situated near the right bronchus intermedius of approximately 
12 x 17 mm in size (Figure 1). This was concerning for tumor recurrence.  The new FDG 
avid area was in a different site as compared to the patient’s original tumor site.  There 
were no other areas of concern. Physical examination showed a thin Caucasian male with 
normal vital signs.  He had no palpable lymphadenopathy, and clinical examination of the 
chest revealed no abnormality.  Bronchoscopy was scheduled with the intent of obtaining 
a transbronchial needle aspiration biopsy. Partially occlusive endobronchial disease was 
found in and around the middle lobe bronchus and conventional biopsies were obtained. 
(Figure 2). Histopathology showed small cell carcinoma. The patient was commenced on 
conventional chemotherapy and radiation for small cell lung cancer.   He continues to 
have good performance status. 
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Figure 1: Pet/CT scan from 2014 in a 55 year old Caucasian male with a history of 
Pancoasts syndrome and a complete response to Iressa.  There is an FDG avid right hilar 
mass confirmed on bronchoscopic biopsy to be small cell carcinoma.  The patient is 
receiving treatment with radiation and chemotherapy. 
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Figure 2: Bronchoscopic view of an endobronchial lesion encountered during the 
bronchoscopic procedure in a 55 year old Caucasian male with a history of Pancoasts 
syndrome that responded to Iressa.  The Olympus bronchoscope finds endobronchial 
disease that is partially occlusive in the right middle lobe. Biopsies showed small cell 
lung cancer.  The patient is undergoing treatment for localized small cell lung cancer. 
 
 
Discussion 
 
Gefitinib is an EGFR tyrosine kinase receptor blocker. It was the first generation of 
EGFR blockers used to treat patients with advanced non-small cell lung cancer who had 
failed chemotherapy.3 Although NSCLC is the most common type of lung cancer, EGFR 
gene mutations occur in about 10% of NSCLC tumors, as assessed by the National 
Cancer Institute.  Gefitinib is intended for the treatment of patients whose tumors express 
the most common types of EGFR mutations in NSCLC tumors: exon 19 deletions or exon 
21 L858R substitution gene mutations.  The diagnostic test, known as the therascreen 
EGFR RGQ PCR Kit, identifies patients who have these very specific EGFR gene 
mutations. The US Food and Drug Administration announced in 2015 the approval of 
gefitinib for first-line treatment of patients with metastatic non–small cell lung cancer 
(NSCLC) whose tumors contain specific types of epidermal growth factor receptor 
(EGFR) gene mutations. The new approval represented a reversal of an earlier decision 
for the drug in the United States. 
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Gefitinib originally received accelerated approval in 2003 for the treatment of patients 
with advanced NSCLC after progression on platinum chemotherapy. However, the drug 
was withdrawn from the market after confirmatory trials failed to verify clinical benefit; 
at that time, it was not known that the drug effectiveness was limited to mutation-specific 
patients.5  
The FDA approval of gefitinib was based on results from a multicenter, single-group 
clinical trial of 106 patients with metastatic NSCLC that was EGFR mutation–positive 
and previously untreated.  After treatment with gefitinib (250 mg once daily), 50% of 
patients had an objective response.  The response rates were similar in patients whether 
their tumors had EGFR exon 19 deletions or exon 21 L858R substitution mutations.  
These results are complimented by another clinical trial, in which 186 patients had 
metastatic, EGFR-positive NSCLC and received first-line treatment with gefitinib. The 
patients randomly assigned to receive gefitinib had better progression-free survival than 
patients receiving standard chemotherapy (such as four to six cycles of 
carboplatin/paclitaxel).6 Thus, the current approval is for a patient population, notably 
EGFR mutation–positive patients who were previously untreated, which is different than 
that of the 2003 approval. 
In clinical trials, groups of patients with stages three and four lung cancer receiving 
gefitinib experienced a significantly longer period of progression-free survival (9.2 
months) compared with patients who received platinum/Taxanes (6.3 months).  Toxicity 
was tolerable for both groups and grade 3/4 adverse events were rare. The patient in the 
present report had a very favorable response to gefitinib when conventional 
chemotherapy had been relatively unsuccessful. The patient in the present report was not 
tested for genetic mutations and had a diagnosis of undifferentiated non-small cell 
carcinoma.  State of the art treatment for advanced unresectable non-small cell lung 
cancer includes DNA testing to identify tumors that are EGFR positive. Treatment is 
usually initiated with newer EGFR blockers such as erlotinib.  Response rates of patients 
with EGFR positive tumors treated with erlotinib are high.  Patients with adenocarcinoma 
are more likely to exhibit the EGFR, although even these patients are in a minority group.  
 
Side effects of gefitinib include nausea, emesis, reduced appetite, rash itching, acne and 
weakness. Gefitinib may cause serious adverse effects including interstitial lung disease, 
liver damage, gastrointestinal perforation, severe diarrhea, and ocular disorders. The most 
common adverse effects are diarrhea and skin reactions (including rash, acne, dry skin, 
and pruritus). 
There is documented evidence of development of small cell lung cancer in patients 
treated with tyrosine kinase inhibitors.7,8 Our patient had been treated for more than ten 
years with gefitinib, which is a much longer time period than is documented in other 
studies for the development of small cell lung cancer that.  Previous authors have 
suggested mechanisms that may account for the switch between non-small cell lung 
cancer of epithelial origin and small cell lung cancer.7 These authors’ hypotheses include 
the possibility of de-differentiation of a well-defined epithelial cancer to a small cell lung 
cancer or a second possibility, such as the co-existence of two succinct progenitor types 
of cell from epithelial and neuroendocrine origins, these cells being present at the initial 
cancer presentation.  Yet a third mechanism could be the existence of both types of 
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established tumor but with small cell lung cancer being present in very small amounts 
that can be missed through sampling error.  Taken together, it is our view that there is a 
loss of epithelial cellular differentiation, by blockade with tyrosine kinase 
inhibitors.  This may allow the cells to seek another pathway of differentiation to a 
different cell type.  This leads to histologic transformation. 
 
Studies in vitro have shown that chronically adapted non-small cell lung cancer cell lines 
have induction of fibroblast growth factor mRNA and protein.9 These in vitro studies 
suggest that other proteins that have adapted in cells as a result of chronic stimulation do 
occur, and may therefore become subsequent targets for the development of other novel 
medications to target treatment.  
 
There is relatively new data regarding lung cancer screening.  Current guidelines include 
recommendations for patients between ages 55 to 80 years old with a 30 pack year 
smoking history.  There is a twenty percent improvement in survival in the CT scan 
screened patient cohort compared to those followed by chest X ray.  The National 
Comprehensive Cancer Network (NCCN) guidelines also suggest continued follow up 
with CT scans for patients with lung cancer to monitor their responses to treatment. We 
support the idea of continued follow up, since our patient in this report has developed 
either another primary tumor albeit of a different histological type or histologic 
transformation of the original disease.  In this present patient, development of new 
malignancy may be related to those risk factors that initiated the original tumor.  The 
other possibilities include a loss of effectiveness of gefitinib and/or interference with 
cellular mechanisms that may protect the body against subsequent tumor initiation. For 
each interaction with a receptor, there is another effect on the cell that will trigger another 
series of molecular mechanisms that affects the cell in a different way.  Lung cancer 
patients with metastatic disease should be followed every three to six months with a CT 
scan.  Most patients treated with EGFR blockade therapy are treated between one to two 
years before they relapse. It is uncommon for patients to be maintained on EGFR 
blockade for eleven years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34
Cooper: Lung Cancer response to Gefitinib
Published by Marshall University's Joan C. Edwards School of Medicine, 2018
References 
 
1. American Cancer Society Cancer facts and Figures.  American Cancer Society, Atlanta, GA USA 
2012. 
 
2. Hirsch FR, Varella-Garcia M, Bunn PA, Di maria MV, Veve R, Bremmes RM et al. Epidermal 
growth factor receptor in non small cell lung cancer. N Engl J Med. 2002;346:92-98. 
 
3. Paez JG, Janne PA, Lee JC, Tracy S Greulich H, Gabriel S et al. EGFR mutations in lung cancer: 
correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. 
 
4. Engelman JA, Janne PA. Mechanisms of acquired resistence to epidermal growth factor receptor 
tyrosine kinase inhibitors in non small cell lung cancer. Clin Cancer Res. 2008;14:2895-2899. 
 
5. Fukuoka M et al. Biomarker analyses and final overall survival results from a phase III, 
randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected 
patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011Jul 20;29(21):2866-
74. doi: 10.1200/JCO.2010.33.4235. 
 
6. Douillard JY et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a 
phase-IV, open-label, single-arm study. Br J Cancer. 2014 Jan 7;110:55-62. doi: 10.1038/bjc.2013.721 
 
7. Jiang S, Zhao J, Wang M et al. Small-cell lung cancer transformation in patients with pulmonary 
adenocarcinoma: a case report and review of literature. Medicine. 2016;95(6):e2752. 
 
8. Sequist LV, Waltman BA, Santagata DD et al.  Genotypic and histologic evolution of lung cancers 
acquiring resistance to EGFR inhibitors.  Science Translational Medicine. 2011;3(75):75ra26.  
 
9. Ware KE, Marshall ME, Heasley LR et al. Rapidly acquired resistence to EGFR tyrosine kinase 
inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. B PLoS One. 
2010;5(11)e14117.       
 
 
 
 
 
 
 
 
 
 
 
35
Marshall Journal of Medicine, Vol. 4 [2018], Iss. 1, Art. 8
https://mds.marshall.edu/mjm/vol4/iss1/8
DOI: http://dx.doi.org/10.18590/mjm.2018.vol4.iss1.8
